For research use only. Not for therapeutic Use.
Vonafexor（Cat No.:I015392）is a selective agonist of the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid, lipid, and glucose metabolism. Primarily investigated for its potential in treating chronic liver conditions like nonalcoholic steatohepatitis (NASH) and hepatitis B and C, vonafexor modulates metabolic pathways to reduce liver fat accumulation and inflammation. Its activation of FXR supports liver health by improving insulin sensitivity and reducing fibrosis. Vonafexor’s targeted mechanism makes it a promising candidate for metabolic and liver-related disorders, with ongoing research into its therapeutic efficacy.
| Catalog Number | I015392 |
| CAS Number | 1192171-69-9 |
| Molecular Formula | C₁₉H₁₅Cl₃N₂O₅S |
| Purity | ≥95% |
| IUPAC Name | 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid |
| InChI | InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26) |
| InChIKey | XLGQSYUNOIJBNR-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl |
| Reference | [1]. Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690.<br>[2]. Fiorucci S,et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10. |
